MX1 and melanoma: Other studies describe dolastatin 10 (326) activity against ovarian carcinoma xenografts as well as mouse P388 and L1210 leukemia, B16 melanoma, M5076 sarcoma, human LOX melanoma, and MX-1 breast cancer xenografts [736,737,738].